Results 81 to 90 of about 20,782 (204)

Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected Patients

Journal of the International Association of Providers of AIDS Care, 2019
Non-nucleoside reverse-transcriptase inhibitor plus integrase strand transfer inhibitor–based dual therapies are an attractive simplification, nucleoside reverse transcriptase inhibitor-sparing strategy for experienced human immunodeficiency virus ...
Niccolò Riccardi MD, Filippo Del Puente MD, Lucia Taramasso MD, Antonio Di Biagio MD   +3 more
doaj   +1 more source

SMARCA4‐Deficient Undifferentiated Thoracic Tumor: Clinical Features and Prognosis of a Case Series and Literature Review

The Clinical Respiratory Journal, Volume 20, Issue 1, January 2026.
Our manuscript presents detailed presentations of case series of thoracic SMARCA4‐UT, and we report a unique case of diaphragmatic metastases and, interestingly, the occurrence of brain metastasis in one patient, which is a rare phenomenon in SMARCA4‐UT.
Fangzhen Shan, Shuntao Liang, Youwen Zhang, Wei Wu, Guangxia Yang, Mei Yan, Xuemei Zhang, Yumao Miao, Linlin Liu, Jingjing Cai, Zhitao Shi, Bangdong Liu, Nannan Zhang   +12 more
wiley   +1 more source

Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine (LA‐I CAB + RPV) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations

HIV Medicine, Volume 27, Issue 1, Page 42-57, January 2026.
Abstract Background When using long‐acting injectable cabotegravir and rilpivirine (CAB + RPV) in individuals with viraemia, beyond small cohorts, little is known about baseline characteristics, virological failure outcomes, resistance emergence, re‐suppression and discontinuation.
Alexa Elias, Chloé Pasin, Melanie Smuk, Amy Paterson, Chloe M. Orkin   +4 more
wiley   +1 more source

Dolutegravir – a review of the pharmacology, efficacy, and safety in the treatment of HIV

Drug Design, Development and Therapy, 2015
Christopher E Kandel,1 Sharon L Walmsley1,21Department of Medicine, University of Toronto, Toronto, ON, Canada; 2Division of Infectious Diseases, University Health Network, Toronto, ON, CanadaAbstract: Dolutegravir is the newest integrase strand transfer
Kandel CE, Walmsley SL
doaj  

Genetic diversity and baseline drug resistance of South African HIV-1 Integrase sequences prior to the availability of Integrase strand-transfer inhibitors [PDF]

, 2020
Dominik Brado
openalex   +1 more source

Intersections of vitamin D deficiency, HIV and chronic liver diseases

HIV Medicine, Volume 27, Issue 1, Page 4-17, January 2026.
Abstract Objectives Despite effective antiretroviral therapy (ART), chronic liver diseases remain a leading cause of morbidity and mortality among people with HIV, with metabolic dysfunction–associated steatotic liver disease (MASLD) now the predominant etiology. Vitamin D deficiency is also highly prevalent in this population.
Francesca Farina, Aurgho Datta, Suzanne N. Morin, Sahar Saeed, Bertrand Lebouche, Giovanni Guaraldi, Salvatore Petta, Giada Sebastiani   +7 more
wiley   +1 more source

Raltegravir: first in class HIV integrase inhibitor

Therapeutics and Clinical Risk Management, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Zelalem Temesgen, Dawd S Siraj
doaj  

People living with HIV on modern antiretrovirals do not display a pro‐atherogenic lipid profile and have similar body composition compared to healthy controls

HIV Medicine, Volume 27, Issue 1, Page 86-95, January 2026.
Abstract Objectives Alterations in lipids and apolipoproteins contribute to cardiovascular disease (CVD) and are common in people with HIV. The aim of our study was to compare lipid profiles and body composition between people with and without HIV and to explore whether any associations with HIV could be explained by socio‐demographic, clinical ...
S. Savinelli, A. Heeney, W. Tinago, A. A. Garcia Leon, P. McGettrick, A. G. Cotter, I. Walsh, M. Fitzgibbon, C. A. Sabin, P. W. G. Mallon, E. R. Feeney, on behalf of the HIV UPBEAT study group   +11 more
wiley   +1 more source

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

Optimizing the Multimerization Properties of Quinoline-Based Allosteric HIV-1 Integrase Inhibitors

Viruses
Allosteric HIV-1 Integrase (IN) Inhibitors or ALLINIs bind at the dimer interface of the IN, away from the enzymatic catalytic site, and disable viral replication by inducing over-multimerization of IN.
Jian Sun, Jacques J. Kessl
doaj   +1 more source